These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

538 related items for PubMed ID: 25858810

  • 1. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
    Sanchorawala V, Brauneis D, Shelton AC, Lo S, Sun F, Sloan JM, Quillen K, Seldin DC.
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.
    Huang X, Wang Q, Chen W, Zeng C, Chen Z, Gong D, Zhang H, Liu Z.
    BMC Med; 2014 Jan 06; 12():2. PubMed ID: 24386911
    [Abstract] [Full Text] [Related]

  • 4. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC, Heitner SB, Dibb W, Meyers G, Smith SD, Abar F, Kovacsovics T, Perez-Avraham G, Stentz A, Frires R, Dibb J, Maziarz RT.
    Clin Lymphoma Myeloma Leuk; 2014 Oct 06; 14(5):424-430.e1. PubMed ID: 24650974
    [Abstract] [Full Text] [Related]

  • 5. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K, Skinner M.
    Bone Marrow Transplant; 2001 Oct 06; 28(7):637-42. PubMed ID: 11704785
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
    Cowan AJ, Klippel ZK, Stevenson PA, Hyun TS, Tuazon S, Becker PS, Green DJ, Holmberg LA, Coffey DG, Gopal AK, Libby EN.
    Amyloid; 2016 Dec 06; 23(4):254-259. PubMed ID: 27879147
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
    Nguyen VP, Landau H, Quillen K, Brauneis D, Shelton AC, Mendelson L, Rahman H, Sloan JM, Sarosiek S, Sanchorawala V.
    Biol Blood Marrow Transplant; 2018 Sep 06; 24(9):1823-1827. PubMed ID: 29933072
    [Abstract] [Full Text] [Related]

  • 10. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke RP, Ho AD, Goldschmidt H.
    Br J Haematol; 2004 Dec 06; 127(5):543-51. PubMed ID: 15566357
    [Abstract] [Full Text] [Related]

  • 11. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.
    Batalini F, Econimo L, Quillen K, Sloan JM, Sarosiek S, Brauneis D, Havasi A, Stern L, Dember LM, Sanchorawala V.
    Biol Blood Marrow Transplant; 2018 Jan 06; 24(1):127-132. PubMed ID: 28865972
    [Abstract] [Full Text] [Related]

  • 12. Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
    Gimsing P, Hjertner Ø, Abildgaard N, Andersen NF, Dahl TG, Gregersen H, Klausen TW, Mellqvist UH, Linder O, Lindås R, Tøffner Clausen N, Lenhoff S.
    Bone Marrow Transplant; 2015 Oct 06; 50(10):1306-11. PubMed ID: 26121108
    [Abstract] [Full Text] [Related]

  • 13. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.
    Afrough A, Saliba RM, Hamdi A, Honhar M, Varma A, Cornelison AM, Rondon G, Parmar S, Shah ND, Bashir Q, Hosing C, Popat U, Weber DM, Thomas S, Orlowski RZ, Champlin RE, Qazilbash MH.
    Biol Blood Marrow Transplant; 2018 Nov 06; 24(11):2197-2203. PubMed ID: 30016656
    [Abstract] [Full Text] [Related]

  • 14. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.
    Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM, Berk JL, Quillen K, Anderson JJ, Comenzo RL, Skinner M.
    Bone Marrow Transplant; 2004 Feb 06; 33(4):381-8. PubMed ID: 14676787
    [Abstract] [Full Text] [Related]

  • 15. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
    Sanchorawala V, Wright DG, Quillen K, Finn KT, Dember LM, Berk JL, Doros G, Fisher C, Skinner M, Seldin DC.
    Bone Marrow Transplant; 2007 Sep 06; 40(6):557-62. PubMed ID: 17589534
    [Abstract] [Full Text] [Related]

  • 16. Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.
    Sanchorawala V, Hoering A, Seldin DC, Finn KT, Fennessey SA, Sexton R, Mattar B, Safah HF, Holmberg LA, Dean RM, Orlowski RZ, Barlogie B.
    Bone Marrow Transplant; 2013 Nov 06; 48(12):1537-42. PubMed ID: 23852321
    [Abstract] [Full Text] [Related]

  • 17. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
    Aypar E, İzzettin FV, Akı ŞZ, Sancar M, Yeğin ZA, Türköz-Sucak G.
    J Oncol Pharm Pract; 2018 Jun 06; 24(4):281-289. PubMed ID: 29284356
    [Abstract] [Full Text] [Related]

  • 18. Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.
    Gertz MA, Lacy MQ, Dispenzieri A, Buadi FK, Dingli D, Hayman SR, Kumar SK, Leung N, Lust J, Rajkumar SV, Russell SJ, Suman VJ, Le-Rademacher JG, Hogan WJ.
    Cancer; 2016 Jul 15; 122(14):2197-205. PubMed ID: 27142462
    [Abstract] [Full Text] [Related]

  • 19. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.
    Oke O, Sethi T, Goodman S, Phillips S, Decker I, Rubinstein S, Concepcion B, Horst S, Jagasia M, Kassim A, Harrell SL, Langone A, Lenihan D, Rawling KT, Slosky D, Cornell RF.
    Biol Blood Marrow Transplant; 2017 Sep 15; 23(9):1473-1477. PubMed ID: 28546074
    [Abstract] [Full Text] [Related]

  • 20. Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.
    Landau H, Smith M, Landry C, Chou JF, Devlin SM, Hassoun H, Bello C, Giralt S, Comenzo RL.
    Leukemia; 2017 Jan 15; 31(1):136-142. PubMed ID: 27560108
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.